Outcome of local application of amifostine (WR-1065) on epirubicin-induced oral mucositis. A phase II study

Anticancer Research

Volumn 24, Issue 5 B, 2004, Pages 3263-3267

  Stokman, M A ^a   Wachters, F M ^a   Koopmans, P ^a   Burgerhof, J G M ^a   Groen, H J M ^a   Spijkervet, F K L ^a   Uges, D R A ^a   Hospers, G A P ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Amifostine; Cytoprotection; Mucositis; WR 1065

Indexed keywords

2 (3 AMINOPROPYLAMINO)ETHANETHIOL; AMIFOSTINE; DEXAMETHASONE; EPIRUBICIN; GEMCITABINE; ONDANSETRON;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EPITHELIUM CELL; FEEDING DISORDER; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MOUTH MUCOSA; MUCOSA INFLAMMATION; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SCORING SYSTEM; VALIDATION PROCESS;

AGED; AMIFOSTINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; EPIRUBICIN; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MOUTH MUCOSA; PAIN; STOMATITIS; TREATMENT OUTCOME;

EID: 6344250754     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Berger AM and Kilroy TJ: Oral complications. In: Cancer: Principles and Practice of Oncology (DeVita VT, Hellman S, and Rosenberg SA eds). Philadelphia, Lippincott-Raven, 1997, pp 2714-2725.
2. Sonis ST: Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol 34: 39-43, 1998.
3. Culy CR and Spencer CM: Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome. Drugs 61: 641-684, 2001.
4. Hospers GAP, Eisenhauer EA and de Vries EGE: The sulfhydryl containing compounds WR-2721 and glutathione as radio- and chemoprotective agents. A review, indications for use and prospects. Br J Cancer 80: 629-638, 1999.
5. Capizzi RL: Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: Laboratory and clinical aspects. Sem Oncol 26: 72-81, 1999.
6. Hartmann JT, von Vangerow A, Fels LM, Knop S, Stolte H, Kanz L and Bokemeyer C: A randomized trial of amifostine in patients with high-dose VIC chemotherapy plus autologous blood stem cell transplanation. Br J Cancer 84: 313-320, 2001.
7. Kemp G, Rose P, Lurain J, Berman M, Manetta A, Roullet B, Homesley H, Belpomme D and Glick J: Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 14: 2101-2112, 1996.
8. Planting AST, Catimel G, de Mulder PHM, de Graeff A, Hoppener F, Verweij J, Oster W and Vermorken JB: Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer. Ann Oncol 10: 693-700, 1999.
9. Bourhis J, De Crevoisier R, Abdulkarim B, Deutsch E, Lusinchi A, Luboinski B, Wibault P and Eschwege F: A randomized study of very accelerated radiotherapy with and without amifostine in head and neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 46: 1105-1108, 2000.
10. Koukourakis MI, Kyrias G, Kakolyris S, Kouroussis C, Frangiadaki C, Giatromanolaki A, Retalis G and Georgoulias V: Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized phase II study. J Clin Oncol 18: 2226-2233, 2000.
11. Schonekas KG, Wagner W and Prott FJ: Amifostine - a radioprotector in locally advanced head and neck tumors. Strahlenther Onkol 175 Suppl 4: 27-29, 1999.
12. Dendale R, Bourhis J, Diawara O, Eschwege F, Habboubi N, and Guichard M: Effect of systemic and topical administration of amifostine on radiation-induced mucositis in mice. Proc Am Soc Clin Oncol 16: 64, 1997.
13. Montana GS, Anscher MS, Mansbach CM, Daly N, Delannes M, Clarke-Pearson D and Gaydica EF: Topical application of WR-2721 to prevent radiation-induced proctosigmoiditis. A phase I/II trial. Cancer Cytopathology 69: 2826-2830, 1992.
14. Theunissen DJ, Koopmans P, Hospers GAP, Stokman MA, Groen HJM and Uges DRA: Op zoek naar een succesvolle toepassing van WR-1065. (In search of a successful application of WR-1065. Active metabolite of amifostine in the prevention of mucositis). Pharm Weekbl 135: 566-570, 2000.
15. Calabro-Jones M, Fahey RC, Smoluk GD and Ward JF: Alkaline phosphatase promotes radioprotection and accumulation of WR-1065 in V79-171 cells incubated in medium containing WR-2721. Int J Radiat Biol 47: 23-27, 1985.
16. Calabro-Jones M, Aguilera JA, Ward JF, Smoluk GD and Fahey RC: Uptake of WR-2721 derivatives by cells in culture: identification of the transported form of the drug. Cancer Res 48: 3634-3640, 1988.
17. Sonis ST, Eilers JP, Epstein JB, LeVeque FG, Liggett Jr WH, Mulagha MT, Peterson DE, Rose AH, Schubert MM, Spijkervet FKL and Wittes JP: Validation of a new scoring system for the assessment of clinical trial research of oral mucositis induced by radiation or chemotherapy. Mucositis Study Group. Cancer 85: 2103-2113, 1999.
18. Wymenga ANM, Spijkervet FLK, Timens W, Timmer-Bosscha H, Sluiter WJ, de Vries EGE and Mulder NH: A new in vitro assay for quantitation of chemotherapy-induced mucositis. Br J Cancer 76: 1062-1066, 1997.
19. Stokman MA, Spijkervet FKL, Wymenga ANM, Burlage FR, Timens W, Roodenburg JLN and de Vries EGE: Quantification of oral mucositis due to radiotherapy by determining viability and maturation of epithelial cells. J Oral Pathol Med 31: 153-157, 2002.
20. Korst AE, Vermorken JB and van der Vijgh WJ: High-performance liquid chromatographic assay using electrochemical detection for the combined measurement of amifostine, WR 1065 and the disulfides in plasma. J Chromatogr B Biomed Sci Appl 693: 167-174, 1997.
21. Van Putten JW, Eppinga P, Erjavec Z, de Leede G, Nabers J, Smeets JB, Th Sleijfer D and Groen HJ: Activity of high-dose epirubicin combined with gemcitabine in advanced non-small-cell lung cancer: a multicenter phase I and II study. Br J Cancer 82: 806-811, 2000.
22. Shaw LM, Turrisi AT, Glover DJ, Bonner HS, Norfleet AL, Weiler C and Kligerman MM: Human pharmacokinetics of WR-2721. Int J Radiat Oncol Biol Phys 12: 1501-1504, 1986.
23. Utley JF, Seaver N, Newton GL and Fahey RC: Pharmacokinetics of WR-1065 in mouse tissue following treatment with WR-2721. Int J Radiat Oncol Biol Phys 10: 1525-1528, 1984.
24. Wachters FM, van Putten JWG, Kramer H, Erjavec Z, Eppinga P, Strijbos JH, de Leede GPJ, Boezen HM, de Vries EGE and Groen HJM: First-line gemcitabine with cisplatin or epirubicin in advanced non-small-cell lung cancer: a phase III trial. Br J Cancer 89: 1192-1199, 2003.